Project Grant R41AG087802
Award Date
9/25/24
Completion Date
8/31/25
Dollars Obligated
$473K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Lexington, MA 02420, USA
Similar Awards
This federal Project Grant award of $994,436 from the National Institute on Aging (CFDA 93.866 Aging Research program) to Transchromix LLC supports the development of novel brain-penetrant drugs for Alzheimer's disease (AD) therapeutics. The research aims to investigate the role of the histone methyltransferase G9A in AD pathogenesis and evaluate the mechanism of action of a G9A-targeted drug, MS1262, which has shown promise in restoring cognitive and affective functions in an AD mouse model....
The National Institute on Aging (NIA) awarded a $919,106 Project Grant (CFDA 93.866 - Aging Research) to the Sanford Burnham Prebys Medical Discovery Institute to conduct research on "Discovery and Optimization of APOE4 Correctors for the Treatment of Alzheimer's Disease." The 5-year project aims to develop small molecules that can functionally correct the detrimental effects of the APOE4 genetic variant, which is the strongest known risk factor for Alzheimer's disease. The research...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $805,738 to the Battelle Memorial Institute's Pacific Northwest National Laboratory to conduct research on the impact of brain lipoprotein structure and composition on amyloid beta metabolism and Alzheimer's disease. The key objectives are to: Assess the influence of different apolipoprotein E (APOE) isoforms on the distribution, composition, and amyloid beta binding capacity of brain...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a multi-target peptide drug for the treatment of Alzheimer's disease (AD). The project aims to demonstrate the in vivo efficacy of the peptide drug "ALZ100" in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The key activities include determining the therapeutic concentration of ALZ100 in the brain, and evaluating...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Virogenics, Inc. provides $2,432,649 in funding to support the development of CMS121, a novel small molecule drug candidate for the treatment of Alzheimer's disease (AD). The key objectives are to: 1) Conduct 13-week toxicology studies in rats and dogs to enable longer-term clinical trials of CMS121 in human subjects with mild to moderate AD, and 2) Develop a tablet formulation of CMS121 to replace...
This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866, the Aging Research program, provides $835,417 in funding to the Icahn School of Medicine at Mount Sinai (ISMMS) to develop novel lipid nanoparticle (LNP) formulations for delivering nucleic acid therapeutics across the blood-brain barrier to treat Alzheimer's disease (AD). The key objectives are to synthesize BBB-crossing lipids, formulate LNP libraries, elucidate trafficking pathways, engineer targeted...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,041,646.00 to Cenna Biosciences Inc. to support the early clinical development of a novel peptide drug candidate, modified P8 (MP8), for the treatment of Alzheimer's disease. The award will fund activities to enable a first-in-human clinical study, including CMC work, a pre-IND meeting with the FDA, IND submission, and the execution of Phase 1 clinical trials of MP8. The project aims to...
This $500,000 Project Grant was awarded by the National Institute on Aging under the Aging Research federal grant program (CFDA 93.866) to Neucyte Inc., a minority-owned small business. The funding supports the development of a nanoluciferase-based microphysiological systems (MPS) platform to enable high-throughput screening of potential Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. Neucyte will leverage human induced pluripotent stem cell technology to create scalable,...
This Project Grant award from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) provides $3,357,206 to Allyx Therapeutics Inc. to conduct a clinical evaluation of the investigational compound BMS-984923 for the treatment of Alzheimer's disease (AD). The key objectives are to develop BMS-984923 as a novel, disease-modifying therapy for AD by targeting the underlying mechanism of synapse loss. Preclinical studies have demonstrated that this small molecule can...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...